Key statistics
On Friday, Lipocine Inc (LPCN:NAQ) closed at 3.12, 16.09% above the 52 week low of 2.68 set on May 12, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.14 |
---|---|
High | 3.25 |
Low | 3.11 |
Bid | 3.07 |
Offer | 3.32 |
Previous close | 3.17 |
Average volume | 34.27k |
---|---|
Shares outstanding | 5.35m |
Free float | 5.19m |
P/E (TTM) | -- |
Market cap | 16.96m USD |
EPS (TTM) | -1.02 USD |
Data delayed at least 15 minutes, as of Jul 18 2025 20:53 BST.
More ▼
- Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
- Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
- Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
- Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
- Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
- Lipocine Announces License and Supply Agreement for TLANDO® in Brazil
More ▼